Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanreotide - Ipsen

Next Previous
X
Search
Drug Profile

Lanreotide - Ipsen

Alternative Names: Angiopeptin; BIM 23014; BIM 23014C; BM 23014; Dermopeptin; Ipstyl; ITM-014; ITM-014T; Lanreotide acetate; Lanreotide Autogel; Lanreotide PRF; Somatulina; Somatuline; Somatuline Autogel; Somatuline Depot; Somatuline LA; Somatuline LP

Latest Information Update: 12 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northwell Health; Tulane University
  • Developer Ipsen; Ipsen Biopharmaceuticals; Northwell Health; Radboud University Nijmegen Medical Centre; Teijin Pharma
  • Class Antineoplastics; Cyclic peptides; Eye disorder therapies; Pancreatic hormones; Pituitary hormone release inhibiting hormones; Urologics; Vascular disorder therapies
  • Mechanism of Action Growth hormone-releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly; Pituitary cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly; Gigantism; Graves ophthalmopathy; Malignant carcinoid syndrome; Neuroendocrine tumours; Pituitary cancer
  • Phase II Gastro-oesophageal reflux; Gastrointestinal motility disorders; Pancreatic cancer
  • Discontinued Atherosclerosis; Breast cancer; Carcinoma; Coronary artery restenosis; Diabetic retinopathy; Digestive system disorders; Gastrointestinal cancer; Intestinal obstruction; Leiomyoma; Lung cancer; Polycystic kidney disease; Polycystic liver disease; Portal hypertension; Prostate cancer; Rheumatic disorders

Most Recent Events

  • 05 Aug 2024 UZ Brussel completes a phase II trial in Gastroesophageal reflux in Belgium (SC, Injection) (EUCT2013-004232-29)
  • 13 Jan 2023 Ipsen completes a phase III trial in Neuroendocrine tumours (Inoperable/Unresectable, Late-stage, Metastatic disease) in China (NCT04852679)
  • 07 Jun 2022 Merck completed a phase I/II PLANET trial in Neuroendocrine tumours (Second-line therapy or greater, Metastatic disease, Late-stage disease, Combination therapy) in USA (IV), in June 2022 (NCT03043664)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top